BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Biochemicals (RHHBY)


7/16/2009 9:05:45 AM

The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. The two licenses with RMS complement Enigma's existing patent portfolio as well as intellectual property licensed by Celera Diagnostics for real-time PCR thermal cyclers.

Financial terms were not disclosed.

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licenses from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

SOURCE Enigma Diagnostics Limited

CONTACT: UK Contact, Enigma Diagnostics, Deborah Cordingley,
+44-1980-590131, deborah.cordingley@enigmadiagnostics.com; or US Contact,
Media, Andrew Mielach, amielach@rlcinc.com, or Investors, Cecelia Heer,
cheer@rlcinc.com, both of Richard Lewis Communications, Inc.,
+1-212-827-0020, for Enigma Diagnostics Limited

Web site: http://www.enigmadiagnostics.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES